SRTS logo

SENSUS HEALTHCARE INC

SRTSNASDAQ
πŸ† #4467 by market capEarnings Oct 29 Β· PostUS Equity
$654.00β–² $15.30 (+2.34%)
Simulated price
πŸ””
Track SRTS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.3%
7dβ–² 20928.9%
14dβ–² 21484.2%
30dβ–² 18270.8%
ytdβ–² 16541.2%
1yβ–² 20530.9%
🏦Market Cap
$49M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-34.3%
Declining
πŸ“ŠGross Margin
36.4%
Healthy
πŸ’΅FCF Margin
-39.8%
Thin
βš–οΈP/S Ratio
2.8x
Cheap
Otter Score
88
Very Good

Trading Snapshot

Day Range
$647.81 – $664.97
52-Week Range
$2.66 – $5.49
Volume
$2.25B
Avg Volume
$2.90B
Shares Outstanding
16.5M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$27M
Last Q Revenue
$2M
P/E Ratio
-3.2
P/S Ratio
2.8x
EPS (TTM)
$-0.94
Dividend Yield
0.00%
Dilution (1yr)
βˆ’0.7%

Why Investors Own SRTS

  • βœ“High-growth profile β€” revenue up +23.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 50% gross margin and 14% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SRTS logo

SENSUS HEALTHCARE INC

SRTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$27Mβ–Ό βˆ’34.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
43.2%β–Ό βˆ’26.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$10Mβ–Ό βˆ’227.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$332Kβ–Ό βˆ’130.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
16.3Mβ–Ό βˆ’0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$21Mβ–Ό βˆ’$51K YoY
StockOtter Β· stockotter.space

About SENSUS HEALTHCARE INC

Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
88/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates